Work

Everolimus (E) plus bevacizumab (B) is effective first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) with papillary features (PF): Results from a phase II trial.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.6_suppl.627

Authors: Darren R. Feldman, Chung-Han Lee, Ana M. Molina, Andrea Knezevic, Yingbei Chen, Joshua Chaim, Devyn Taylor Coskey, Yasser Ged, Satish Tickoo, Victor E. Reuter, Sujata Patil, Han Xiao, Jahan Aghalar, Arlyn J. Apollo, Maria Isabel Carlo, Robert J. Motzer, Martin Henner Voss

Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2790928376

Cites:

Cited by: 1

Related to: 10